The trial, to be hosted in Australia, will evaluate if the duo’s bone graft substitute, NB1, is suitable for use in humans, according to an Oct. 25 letter to Bone Biologic stockholders from Jeffrey Frelick, the company’s CEO and president. A clinical trial testing the product in sheep found that the treatment “safely and effectively” promoted spinal fusion.
“We are optimistic that spinal fusion patients will benefit from our solution to the problem of hard-to-heal bones, and we are very excited about the potential to help these patients as we advance NB1 along the development pathway,” he wrote in the letter, which was shared via an Oct. 25 news release. “We believe our effort will be well rewarded not only by patients, but also by caregivers and Bone Biologics stockholders.”
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
